Inobrodib - CellCentric
Alternative Names: CCS-1477Latest Information Update: 28 Jan 2025
At a glance
- Originator CellCentric
- Class Antineoplastics; Fluorobenzenes; Imidazoles; Isoxazoles; Piperidines; Small molecules
- Mechanism of Action P300-CBP transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours
- Preclinical Malignant melanoma
- No development reported Bladder cancer; Lung cancer
Most Recent Events
- 10 Dec 2024 Updated efficacy data from a phase I/IIa trial in Multiple myeloma released by CellCentric
- 07 Dec 2024 Efficacy data from a phase I/IIa trial in Multiple myeloma presented at 66th American Society of Hematology Annual Meeting and Exposition 2024 (ASH-Hem-2024)
- 11 Dec 2023 Updated efficacy and adverse event data from a phase I/IIa trial in Multiple myeloma released by CellCentric